Genetic Testing for Neurologic Disorders: How Can It Help You and Your Patient?

Overview

Next-generation sequencing tests for neurologic disorders have provided an opportunity to screen a large number of genes concurrently. While this increases the likelihood of identifying the genetic mechanism for disease in an individual, it also leads to increasingly complex test reports. This presentation will outline the benefits and limitations of genetic testing for neurologic disorders and provide a framework for interpretation of test results.

Presentation

View the Archived Webinar

  Video length: 58 minutes and 16 seconds

 

Presenters

Image of Emily Lauer, CGC, Genetic CounselorEmily Lauer, CGC
Genetic Counselor
Department of Laboratory Medicine and Pathology
Mayo Clinic

 

 

 

Image of Angela Pickart, CGC
Genetic Counselor
Department of Laboratory Medicine and Pathology
Mayo Clinic

 

 

 

Learning Objectives

  • Recognize the roles and responsibilities of a laboratory genetic counselor.
  • Apply basic genetics concepts to the interpretation of a genetic test report.
  • Navigate the elements of a clinical genetic testing report.
  • Define what is a variant of uncertain significance (VUS) and identify ways to further clarify its significance.
  • Summarize the benefits and limitations of clinical genetic testing.

 

Intended Audience

This webinar is designed for any provider who sees patients with a neurologic disease (e.g., neurologists, psychiatrists, primary care physicians including internists and family care practitioners) as well as pathologists, laboratory directors, and laboratory sendout coordinators.

 

Level of instruction

Intermediate

 

 

Faculty Disclosure

Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.

National Physician Payment Transparency Program

Mayo Medical Laboratories is not an applicable manufacturer or applicable group purchasing organization (GPO). (GPOs, per the Centers for Medicare & Medicaid Services, and this program do not trigger any reporting requirements pursuant to Open Payments[Sunshine Act] legislation.)

 

Note: No credit is offered for the Pediatric Phlebotomy presentations.

MCL Education

MCL Education

This post was developed by our Education and Technical Publications Team.